References
- Deininger MW. Milestones and monitoring in patients with CML treated with imatinib. Hematology Am Soc Hematol Educ Program 2008:419–426.
- Ou J, Vergilio J, Bagg A. Molecular diagnosis and monitoring in the clinical management of patients with chronic myelogenous leukemia treated with tyrosine kinase inhibitors. Am J Hematol 2008;83:296–302.
- Nakamura TM, Morin GB, Chapman KB, Telomerase catalytic subunit homologs from fission yeast and human. Science 1997;277:955–959.
- Meyerson M, Counter CM, Eaton EN, hEST2, the putative human telomerase catalytic subunit gene, is up-regulated in tumor cells and during immortalization. Cell 1997;90:785–795.
- Yang L, Han Y, Saurez Saiz, Minden MD. A tumor suppressor and oncogene: the WT1 story. Leukemia 2007;21:868–876.
- Rasoul NA, Elhalawani N, Nafae MH, Elkaffash DM, Mourad ZI. Telomerase activity in Philadelphia positive chronic myeloid leukaemia. Egypt J Immunol 2004;11:1–8.
- Uziel O, Fenig E, Nordenberg J, Imatinib mesylate (Gleevec) downregulates telomerase activity and inhibits proliferation in telomerase-expressing cell lines. Br J Cancer 2005;92:1881–1891.
- Campbell LJ, Fidler C, Eagleton H, hTERT, the catalytic component of telomerase, is downregulated in the haematopoietic stem cells of patients with chronic myeloid leukaemia. Leukemia 2006;20:671–679.
- Yamada O, Kawauchi K, Akiyama M, Leukemic cells with increased telomerase activity exhibit resistance to imatinib. Leuk Lymphoma 2008;49:1168–1177.
- Inoue K, Ogawa H, Sonoda Y, Aberrant overexpression of the Wilms tumor gene (WT1) in human leukemia. Blood 1997;89:1405–1412.
- Cilloni D, Messa F, Gottardi E, Sensitivity to imatinib therapy may be predicted by testing Wilms tumor gene expression and colony growth after a short in vitro incubation. Cancer 2004;101:979–988.
- Otahalova E, Ullmannova-Benson V, Klamova H, Haskovec C. WT1 expression in peripheral leukocytes of patients with chronic myeloid leukemia serves for the prediction of imatinib resistance. Neoplasma 2009;56:393–397.
- Vardiman JW, Brunning RD, Harris NL. Chronic myeloproliferative diseases. WHO classification of tumoursIn: Jaffe ES, Harris NL, Stein H, Vardiman JW, editors. Pathology and genetics of tumours of the hematopoetic and lymphoid tissues. LyonIARC Press2001. pp15–59.
- Kantarjian H, Sawyers C, Hochhaus A, Hematologic and cytogenetic responses to imatinib mesylate in chronic myelogenous leukemia. N Engl J Med 2002;346:645–652.
- Jones CD, Yeung C, Zehnder JL. Comprehensive validation of a real-time quantitative BCR-ABL assay for clinical laboratory use. Am J Clin Pathol 2003;120:42–48.
- Tauchi T, Nakajima A, Sashida G, Inhibition of human telomerase enhances the effect of the tyrosine kinase inhibitor, imatinib, in BCR-ABL-positive leukemia cells. Clin Cancer Res 2002;8:3341–3347.
- Kreuzer K, Saborowski A, Lupberger J, Fluorescent 5′-exonuclease assay for the absolute quantification of Wilms' tumour gene (WT1) mRNA: implications for monitoring human leukemias. Br J Haematol 2001;114:313–318.
- Svensson E, Vidovic K, Lassen C, Deregulation of the Wilms' tumour gene 1 protein (WT1) by BCR-ABL1 mediates resistance to imatinib in human leukemia cells. Leukemia 2007;21:2485–2494.
- Cao XS, Gu WY, Chen ZX, Hu SY, He J, Cen JN. Bone marrow WT1 gene expression and clinical significance in chronic myelogenous leukemia. Zhonghua Nei Ke Za Zhi 2007;46:277–279.
- Lichtman MA, Lieveld JL. Chronic myelogenous leukemia and related disorders. Williams hematology. In: Beutler E, Lichtman MA, Coller BS, Kipps TJ, editors. 6th edNew YorkMcGraw-Hill2001. pp1125–1136.